Platelet Antibodies of the IgM Class in Immune Thrombocytopenic Purpura

Douglas B. Cines, Susan B. Wilson, Ann Tomaski, and Alan D. Schreiber
Hematology-Oncology Section, Departments of Medicine and Pathology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104

Abstract

The clinical course and response to therapy of patients with immune thrombocytopenic purpura (ITP) are not completely determined by the level of IgG present on the platelet surface. It is possible that antibodies of other immunoglobulin classes also play a role in platelet destruction in some of these patients. Therefore, we studied 175 patients with ITP for the presence of IgM anti-platelet antibodies using radiolabeled polyclonal or monoclonal anti-IgM. We observed that 57% of patients with clinical ITP had increased levels of IgM on their platelets, compared with normal controls and patients with thrombocytopenia who did not have ITP (<10%), (P < 0.01). We obtained similar results using either radiolabeled polyclonal or monoclonal anti-IgM, reagents whose integrity was first characterized using erythrocytes coated with defined amounts of IgM antibody. Among patients with increased platelet-IgM there was a significant correlation both with the presence of increased platelet-C3 as well as the amount of platelet-C3 (P < 0.01, r = 0.53). We demonstrated the presence of warm-reacting IgM anti-platelet antibodies in the plasma of two of these patients who were further studied. The isolated IgM fraction from these two plasmas was able to activate complement and place 3H-C3 on normal platelets. These studies demonstrate the presence of warm-reacting IgM anti-platelet antibodies in some patients with ITP. They suggest that the binding of complement to platelets by IgM antibodies may initiate platelet clearance as well as enhance the effect of IgG antibodies in ITP.

Introduction

Thrombocytopenia in patients with immune thrombocytopenic purpura (ITP) is caused by the accelerated removal of immunoglobulin-coated platelets from the circulation. The most important ligand on the platelet surface recognized by tissue macrophages is IgG, either in the form of antibody or immune complexes. It is less clear, however, whether the measured amount of IgG on the platelet surface, by itself, determines either the extent of the platelet destruction or the magnitude of the thrombocytopenia (1–6). For example, increased amounts of platelet-bound IgG have been detected in some patients whose thrombocytopenia is not believed to be mediated by antiplatelet antibodies (7–10). Furthermore, increased platelet-IgG is detected in occasional patients who have a normal platelet count (7, 8). These data suggest that factors other than the amount of IgG on the platelet influence the recognition and removal of ITP platelets.

One such factor that might accelerate platelet clearance is C3, the third component of complement. In patients with immune hemolytic anemia, for example, the presence of cell-bound C3 influences the rate and site of erythrocyte clearance (11). Several investigators have noted increased amounts of C3 on the platelets of some patients with ITP. This increase in platelet-C3 is generally associated with the presence of increased amounts of platelet-IgG (12–15). However, we have observed that some ITP patients have increased levels of platelet-associated (PA)-C3 with normal levels of PA-IgG (13). In these cases, the deposition of C3 could result from the presence of anti-platelet antibodies of the IgM class that are known to activate complement more efficiently than most IgG antibodies. Indeed, several investigators have recently observed increased amounts of IgM on the platelets of some patients with ITP (15–22). Therefore, we sought to determine if complement-fixing IgM anti-platelet antibodies are, in fact, demonstrable in ITP and could account for the presence of C3 on the platelets of some of these patients. We also sought to determine whether the presence of IgM antibody might help to explain some of the variation in the severity of ITP.

Methods

Patients: We initially studied 127 consecutive patients with idiopathic thrombocytopenic purpura using previously reported criteria for diagnosis (13). Platelet counts in these patients ranged from 5,000 to 258,000/mm³ (96,000±77,000/mm³, mean±2 SD). 104 patients were thrombocytopenic (platelet count < 150,000/mm³) while 23 were in clinical remission at the time of study. 99 patients were untreated, while 28 were taking corticosteroids, eight had undergone splenectomy, two were receiving intravenous gammaglobulin, and one was receiving infusions of vinblastine. We also studied the platelets obtained from 78 normal healthy volunteers and 32 thrombocytopenic patients who did not have a clinical diagnosis of ITP. The causes of thrombocytopenia in these patients included hypersplenism (3), narrow suppression from chemotherapy (1), drug-induced thrombocytopenia (6), hereditary thrombocytopenia (2), chronic lymphocytic leukemia (3), narrow involvement with another malignant (5) or a nonmalignant process (4), narrow hypoplasia (4), disseminated intravascular coagulation (3), and sepsis (1). The mean platelet count in this thrombocytopenic control population was 53,000±33,000/mm³ (mean±2 SD). To compare the binding of monoclonal anti-IgM and polyclonal anti-IgM (see below), we studied an additional 48 patients with untreated ITP, an additional 35 normal controls, and an additional 12 patients who were thrombocytopenic but did not have a clinical diagnosis of ITP.

Measurement of platelet-bound immunoglobulin and complement.

1. Abbreviations used in this paper: ITP, immune thrombocytopenic purpura; NSP, N-succinimidyl(2,3-3H)propionate; PA, platelet associated.

0021-9738/85/04/1183/08 $1.00
Volume 75, April 1985, 1183-1190
Rabbit antiserum against human IgG (gamma chain) was obtained from Calbiochem-Behring Corp., La Jolla, CA. The IgG fraction of rabbit antiserum against human IgM (μ chain) or C3 were obtained from Atlantic Antibodies, Scarborough, ME. The IgG fraction was isolated from anti-IgG antiserum and normal rabbit serum by affinity chromatography using anti-rabbit IgG agarose (Miles Laboratories, Elkhart, IN). Murine monoclonal anti-human IgM (μ chain) was obtained from Bethesda Research Laboratories, Gaithersburg, MD. Each IgG fraction was radiolabeled with 1184 Na (New England Nuclear, Boston, MA) to a specific activity of 1.3-2.1 × 10^6 cpm/μg protein (23).

We determined the level of platelet-bound IgG, IgM, and C3 as well as plasma IgG and IgM anti-platelet antibody activity using the radiolabeled antiglobulin test (13). In this assay, the level of platelet-bound immunoglobulin or C3 is determined by the extent of binding of the specific radiolabeled antiglobulin reagent. Briefly, 1 × 10^4 washed platelets from patients or normal donors were incubated with an aliquot of each labeled ligand for 45 min at 37°C, washed four times, and the platelet-bound radioactivity determined. In the indirect test, 1 × 10^4 washed normal platelets were first incubated with normal or patient plasma in 0.01 M EDTA buffer, washed four times, and then incubated with each labeled ligand. Assays on patient platelets were generally performed using ~1 μg of each heterologous antibody, monoclonal anti-μ chain antibody, or similarly labeled normal rabbit IgG, per 10^9 platelets. Specific binding of rabbit IgG anti-IgM to platelets (i.e., that portion of total binding due solely to the interaction of the anti-IgM antibody with platelet-bound IgM) was first assessed by preincubating platelets with a 100-fold excess of normal rabbit IgG before incubation with 1184-IgG anti-IgM. In addition, we compared the binding to platelets of labeled IgG anti-IgM and labeled normal rabbit IgG not having antibody activity. In experiments in which we measured the binding of monoclonal IgG anti-IgM to platelets, we used the radiolabeled IgG fraction of the parent mouse myeloma line (P3) as the nonimmune control. Binding of 1184-IgG to platelets was <0.05% of the total available radioactivity in all experiments. The extent of binding of each antiglobulin preparation to platelets is expressed as a percentage of the total radioactivity to which the platelet was exposed according to the formula: % binding = (platelet-associated cpm − test tube cpm)/(total cpm − test tube cpm) × 100.

Binding of 1184 anti-IgM to antibody-coated erythrocytes. We first determined the optimal conditions for detecting cell-bound IgM by studying the binding of 1184 anti-IgM to IgM-coated erythrocytes. The IgM fraction of erythrocyte blood group A substance was prepared from human antiserum by gel filtration chromatography (13) and quantitated as protein (24). We then radiolabeled the IgM preparation with tritium using N-succinimidyl(2,3)-3Hpropionate (NSP) (Amersham Corp., Arlington Heights, IL). To tritate this protein, the IgM prepa- ration was dialyzed against 0.1 M borate buffer, pH 8.4. The NSP was evaporated under nitrogen in a glass tube at 0°C just before use. The IgM was then added to the NSP for 15 min at 0°C. The unreacted NSP was then inactivated by the addition of 2 vol of 0.5 M glycine for 5 min at 0°C. We separated the radiolabeled IgM from residual free NSP by applying the protein to a Sephadex G-50 column equilibrated with 0.0035 M phosphate buffer containing 0.12 M KCl, pH 7.4. 1-ml fractions were collected and assayed for 3H in a scintillation counter (Beckman Instruments, Inc., Fullerton, CA). The resultant 3H-labeled IgM had a specific activity of 3.5-10^6 cpm/μg protein. We examined whether the process of trice labeling altered the antibody activity of the IgM anti-A antibody. Type A erythrocytes were incubated with varying concentrations of labeled and unlabeled IgM anti-A and the subsequent binding of 1184-IgM anti-human IgM was determined. Using this technique, we found that the 3H-labeled IgM anti-A had essentially identical antibody activity as unlabeled IgM anti-A.

1 ml of washed erythrocytes (1 × 10^9/ml) prepared from normal type A and type B donors was incubated with varying concentrations of 3H-IgM anti-A at 37°C for 30 min and washed four times in isotonic veronal-buffered saline, pH 7.4. Erythrocyte membranes were then prepared in hypotonic buffer (25), solubilized in Protosol (New England Nuclear), and counted for radioactive emission in a scintillation counter (Beckman Instruments, Inc.). Specific binding of 3H-IgM anti-A to type A erythrocytes was determined by subtracting the amount of binding of the labeled ligand to type B erythrocytes.

We then determined the binding of 1184 anti-IgM to these erythrocytes sensitized with IgM antibody. To perform this study, type A and type B erythrocytes were first sensitized with varying concentrations of 3H-IgM anti-IgA, washed and incubated with 1184-polyclonal or monoclonal anti-human IgM, which contained 1-2 μg of labeled protein, for 45 min at 37°C; the labeled cells were then washed four times and the erythrocyte-associated radioactivity determined. Specific binding of this antibody (i.e., binding due only to the interaction of anti-IgM with IgM anti-A) was defined in two ways. First, IgM-sensitized type A erythrocytes were incubated with varying concentrations (1-50-fold molar excess) of unlabeled rabbit IgG anti-IgM or normal rabbit IgG for 30 min at 37°C before the addition of 1184-IgG anti-IgM, and the erythrocyte-associated radioactivity determined. Specific binding was defined as that portion of the binding of the labeled antiglobulin reagent that could be inhibited by a 50-M excess of unlabeled anti-IgM, but not by a similar concentration of normal rabbit IgG. Second, we determined the difference in the binding of 1184 anti-IgM to IgM-sensitized type A and type B erythrocytes. This difference is a measure of specific binding of labeled anti-IgM because IgM anti-A did not show any measurable specific binding to type B erythrocytes (see Results). In parallel studies we also determined the extent of cross-reactivity of 1184 anti-IgM with cell-bound IgG by measuring its binding to type A erythrocytes that were sensitized with equivalent amounts of 3H-IgG and 3H-IgM anti-A. In order to quantitate the amount of labeled anti-IgM that binds to cell-bound IgM at saturation, type A blood cells that were sensitized with a single concentration of 3H-IgM anti-A were then incubated with varying concentrations of 1184 anti-IgM and the cell-associated radioactivity determined. We also compared the binding of the labeled polyclonal and monoclonal anti-IgM reagents to erythrocytes that were sensitized with varying concentrations of 3H-IgM anti-A.

Preparation of human C3. C3 was isolated from human plasma by the method of Hammer et al. (26) with slight modifications. A 1,200-ml pool of fresh frozen plasma was obtained from two donors (Community Blood Bank, Philadelphia, PA) treated with 50 mM epsilonaminocaproic acid and 1 mM phenylmethylsulfonyl fluoride, and precipitated with 5% polyethylene glycol. The supernatant was applied to a Sepharose L-lysine column to remove plasminogen. 500 ml of this plasma was dialyzed against 0.01 M KCl buffered with 0.01 M K-phosphate pH 7.0, on a DEAE Sephadex column (5 × 10 cm) using a linear salt gradient (1.3-10.5 mmol conductivity). Fractions were analyzed for complement and immunoglobulin proteins by effective molecule titration and Ouchterlony analysis. Trace amounts of IgG, IgA, and C5 were removed by hydroxyapatite chromatography as assessed by Ouchterlony analysis and effective molecule titration of C5. The concentration of the purified C3 was 1.25 mg/ml by radial immunodiffusion and 16,000 hemolytically effective units per milliliter by effective molecule titration. This is similar to the data we observed for the C3 in normal plasma before isolation where C3 (1 mg/ml) had a specific hemolytic activity of 10,000 effective units per milliliter. The resultant protein was analyzed using SDS-7.5% polyacrylamide disc gels which were then stained for protein with Coomassie Blue. The C3 preparation consisted of a single protein band with an apparent molecular weight of 230,000, which produced the characteristic α- and β-chains upon reduction in 2-mercaptoethanol. The eluted protein from alkaline disc gels run in parallel was shown to be C3 by Ouchterlony analysis.

The purified C3 was then radiolabeled with 3H using NSP as above. After radiolabeling, unbound NSP was separated from 3H-C3 using Sephadex G-50. The labeled C3 had a specific activity of ~1.0 × 10^6 cpm/μg C3 and retained 85-95% of its initial hemolytic activity when assayed by effective molecule titration (11, 27). When determining the number of C3 molecules deposited on the platelet surface, we used a
mixture of labeled and unlabeled C3. Between 10 and 40% of the total available C3 in these experiments was tritiated.

Statistics: All statistical analyses, including P values determined by the t-test and linear regression analyses, were performed using the Hewlett-Packard computer (model HP86B, Hewlett-Packard Co., Corvallis, OR).

Results

The purpose of this study was to measure the amount of IgM on platelets from patients with ITP and to compare these results with the amount of IgM on normal platelets using radiolabeled antiluetic reagents. In order to address this question, we first needed to determine the extent to which the binding of labeled anti-IgM depended upon the presence and amount of cell-bound IgM, the extent to which the labeled anti-IgM cross-reacted with cell-bound IgG, and the approximate amount of anti-IgM that bound to each molecule of cell-bound IgM at saturation. Because the amount of IgM on platelets is unknown, we first characterized the binding of radiolabeled anti-IgM to human erythrocytes that were sensitized with known amounts of IgM antibody.

The schema we used to answer these questions is outlined in Fig. 1. In reaction 1, type A or type B (not shown) erythrocytes were sensitized with 3H-labeled IgG or IgM fractions of anti-A antisera. By measuring the resultant cell-bound radioactivity, we were able to prepare erythrocytes sensitized with known amounts of human IgG or IgM. In reaction 2, 125I-labeled rabbit or murine IgG anti-human IgM was then added to these cells to determine the extent of its binding to cell-bound IgG or IgM. In these studies we employed a range of concentrations of IgG and IgM anti-erythrocyte antibodies, which we subsequently determined were comparable to the amounts of each protein present on normal and ITP platelets.

Binding of 125I anti-IgM to IgM-coated erythrocytes. We first examined the binding of labeled IgM anti-A to type A and type B human erythrocytes. As shown in Fig. 2, 3H-IgM anti-A bound to type A erythrocytes in a dose-dependent manner, while it showed little binding to type B cells (<10% of the binding to type A cells). Therefore, any subsequent specific binding of the anti-IgM to these cells reflects almost entirely its interaction with IgM anti-A antibody on the surface of the type A erythrocyte.

Using these erythrocytes, sensitized with known amounts of 3H-IgM antibody, we then determined the binding of 125I rabbit IgG anti-human IgM (Fig. 3). Binding of 125I anti-IgM to type A erythrocytes varied in proportion to the amount of IgM anti-A on the surface of these cells. In contrast, we observed little binding of 125I anti-IgM to type B cells that were sensitized with 3H-IgM anti-A, which confirmed our observation that little IgM anti-A bound to type B erythrocytes. The amount of this nonspecific binding of 125I anti-IgM to type B cells was constant and represented a proportionately smaller percentage of the total binding to type A cells as the amount of IgM antibody was increased (Fig. 3). The extent of specific binding of 125I anti-IgM to IgM-coated erythrocytes was also determined by preincubating these sensitized cells with a 50-M excess of unlabeled antibody or normal rabbit IgG. The binding of labeled anti-IgM to IgM-sensitized erythrocytes was inhibited <10% by the presence of excess normal IgG. In contrast, >90% of the binding was inhibited by a similar concentration of unlabeled anti-IgM. These data indicated that the binding of radiolabeled anti-IgM to IgM-coated erythrocytes depends upon the amount of IgM with which these cells are sensitized.

We then determined whether the 125I anti-IgM cross-reacted with cell-bound human IgG. Type A erythrocytes were first incubated with increasing amounts of 3H-IgM anti-A or 3H-IgG anti-A, and the amount of cell bound antibody was determined (abscissa, Fig. 4). Using erythrocytes coated with equivalent amounts of 3H-IgM or 3H-IgG anti-A, we then measured the binding of 125I anti-IgM. As shown in Fig. 4, there was only a small amount of binding of labeled anti-IgM to erythrocytes that were sensitized with IgG antibody; this cross-reactivity represented <10% of the total binding of anti-IgM at the levels of IgG and IgM present on ITP platelets (see below).

We then determined the approximate amount of anti-IgM which bound to IgM-coated cells when saturating concentrations of anti-IgM were employed (Fig. 5). Erythrocytes were first sensitized with a concentration of IgM anti-A antibody that

![Figure 1. Reaction sequence to assess the binding of radiolabeled anti-IgM to IgM-coated erythrocytes (RBC).](image)

![Figure 2. Binding of 3H-IgM anti-A to type A and type B human erythrocytes (RBC). Specific binding represents the difference between 3H-IgM anti-A binding to each set of erythrocytes (see Methods).](image)
was sufficient to bind ~240 molecules of IgM anti-A per red cell. These cells were then incubated with increasing concentrations of 125I IgG anti-IgM and the cell-bound radioactivity was determined. Saturation was achieved when 20 µg of anti-IgM was added per 10^8 red cells. When these data were analyzed by the method of Scatchard, we found that at saturation approximately one molecule of anti-IgM bound to each molecule of erythrocyte-bound IgM (Fig. 5). Similar results were obtained when these IgM-sensitized cells were incubated with 125I monoclonal anti-IgM (not shown). We then compared the binding of the monoclonal and polyclonal anti-IgM reagents on erythrocytes that were sensitized with varying concentrations of IgM antibody. As shown in Figs. 3 and 6, over the range of IgM found on normal and ITP platelets, approximately the same amount of the 125I-labeled polyclonal and monoclonal anti-IgM antibody bound to each molecule of cell-bound IgM. These studies established that these 125I anti-IgM reagents primarily detect cell-bound IgM, and that they show little cross-reactivity with IgG antibody on the cell surface.

**Figure 3.** Type A or B erythrocytes (RBC) were sensitized with varying amounts of 3H-IgM anti-A (abscissa) and the extent of binding of polyclonal 125I anti-IgM was determined (ordinate). The shaded area represents the amount of 125I anti-IgM adsorbed to an equivalent number of normal platelets.

**Figure 4.** 125I anti-IgM binding to IgM- or IgG-coated erythrocytes (RBC). Type A erythrocytes were sensitized with equivalent amounts (micrograms) of IgG or IgM anti-A antibody before incubation with radiolabeled anti-IgM.

**Figure 5.** Saturation of 125I anti-IgM binding. Erythrocytes (RBC) were sensitized with ~240 molecules of 3H-IgM anti-A/RBC before incubation with increasing amounts of polyclonal 125I anti-IgM. The ratio of bound 125I IgG anti-IgM molecules per RBC to unbound 125I IgG anti-IgM molecules per RBC is shown on the ordinate. The number of molecules of 125I IgG anti-IgM bound per RBC is plotted on the abscissa. The inset depicts a Scatchard plot of the data. The X intercept (234 sites) indicates the number of IgG anti-IgM binding sites at saturation.

IgG, the binding of labeled IgG anti-IgM to platelets was reduced by ~40%; in contrast, >90% of the binding of labeled anti-IgM to normal platelets was prevented by the presence of a 100-fold excess of unlabeled anti-IgM. Therefore, these studies suggest that small but detectable amounts of IgM are present on the surface of normal washed platelets. This amount of 125I anti-IgM which binds to normal platelets is equivalent to that bound to erythrocytes coated with 100–400 molecules of 3H-IgM per cell (shaded area, Fig. 3).

We then studied the binding of 125I anti-IgM to platelets obtained from 127 patients who had a clinical diagnosis of ITP (Table I, Fig. 7). The platelets of these patients bound 0.28±0.41% (mean±2 SD) of the total available radioactivity (Table I, Fig. 7). The platelets from 66 of these 127 patients (52%) showed an increase in the binding of 125I anti-IgM, which was >2 SD from the mean value of the normal population; platelets from 43 patients bound anti-IgM in excess of 3 SD from the mean. In contrast, the binding of normal rabbit IgG by ITP platelets was essentially identical to its binding by normal platelets (Table I). We also studied the platelets from two patients with Waldenström’s macroglobulinemia who had serum concentrations of IgM of 2.5 and 2.8 g/dl and who had platelet counts of 80,000/mm³ and 120,000/mm³, respectively. In both cases, platelet-IgM fell within the normal range. Platelets from only 4 of 32 patients with thrombocytopenia, who did not have a clinical diagnosis of ITP, bound increased amounts of anti-IgM (Fig. 7, Table I). Two of these four had demonstrable drug-dependent (gold,
heparin) antibodies. The level of binding of anti-IgM to platelets from the thrombocytopenic control population as a whole did not differ significantly from the level found in the normal population \( (P > 0.05) \). In contrast, the binding of \[^{125}\text{I}]\text{anti-IgM}\) to platelets from patients with ITP was statistically significantly different from both the normal control population and the thrombocytopenic control population at both 2 SD and 3 SD from the mean \( (P < 0.001) \).

**Comparative binding of \[^{125}\text{I}]\text{anti-C3}\) and \[^{125}\text{I}]\text{anti-IgM}\) to ITP platelets.** We then studied the relationship between the extent of binding of anti-C3 and the amount of PA-IgM and PA-IgG present in our patients with ITP. As shown in Table II, our patients commonly had increased levels of all three proteins. The platelets from 54 of 66 patients which bound increased amounts of anti-IgM also bound increased amounts of anti-C3. In contrast, the platelets from 46 of the 61 patients which bound normal amounts of anti-IgM also bound normal amounts of anti-C3 \( (P < 0.001) \). In the subset of patients having a PA-IgM determination > 3 SD from the mean, the platelets from 39 of these 41 individuals also had increased levels of PA-C3. Furthermore, we observed a relationship between the level of PA-IgM and PA-C3 in these 127 patients with ITP \( (P < 0.01, r = 0.53, \text{Fig. 8}) \). This positive relationship between PA-IgM and PA-C3 was noted in patients with clinically active or inactive ITP, in patients before or after splenectomy, and in patients who were receiving corticosteroids as well as those who were untreated at the time of study. In contrast to the relationship between PA-IgM and PA-C3, an isolated increase in PA-IgG with a concomitant increase in PA-C3 was observed in only 9 of 38 cases. Moreover, we observed only a moderate correlation \( (P = 0.04) \) between the presence of increased PA-IgG, as an independent variable, and the presence of increased PA-C3.

We did not observe a statistically significant relationship between the level of PA-IgM and PA-IgG. In addition, 17 patients, representing 13% of the total ITP population studied, had normal values for PA-IgG, PA-IgM, and PA-C3. 10 of these patients were in clinical remission at the time of study; an additional 3 patients had been started on corticosteroids within 72 h of the time of study.

**Comparative binding of polyclonal and monoclonal anti-IgM to platelets.** Recent studies indicate that monoclonal

---

**Table I. Binding of Polyclonal \[^{125}\text{I}]\text{Rabbit IgG}\) Anti-Human Antibodies to Platelets**

<table>
<thead>
<tr>
<th>Source of platelets</th>
<th>% Binding</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Anti-\text{IgM}</td>
</tr>
<tr>
<td>Normals ((n = 78))</td>
<td>0.09±0.14</td>
</tr>
<tr>
<td>Thrombocytopenic controls ((n = 32))</td>
<td>0.13±0.20</td>
</tr>
</tbody>
</table>

* ° \[^{125}\text{I}]\text{IgG}\) labeled normal rabbit IgG.
‡ Platelet-bound radioactivity \((\text{mean}±2 \text{ SD})\) expressed as a percentage of the total available radioactivity.

---

**Table II. Platelet-associated C3 in ITP**

<table>
<thead>
<tr>
<th></th>
<th>Increased PA-C3</th>
<th>Normal PA-C3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>((n = 127))</td>
<td>((n = 58))</td>
</tr>
<tr>
<td>1 Increased PA-IgM</td>
<td>12</td>
<td>7</td>
</tr>
<tr>
<td>only ((&gt;2 \text{ SD}))</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased PA-IgM</td>
<td>9</td>
<td>2</td>
</tr>
<tr>
<td>only ((&gt;3 \text{ SD}))</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Increased PA-IgM and</td>
<td>42</td>
<td>5</td>
</tr>
<tr>
<td>increased PA-IgG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>only</td>
<td>9</td>
<td>29</td>
</tr>
<tr>
<td>3 Normal PA-IgM and</td>
<td>6</td>
<td>17</td>
</tr>
<tr>
<td>normal PA-IgG</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Figure 7. Platelet-associated IgM in normal controls, thrombocytopenic controls, and patients with ITP.**

**Figure 8. Relationship of PA-IgM to PA-C3 in ITP.**
antibodies which detect human immunoglobulins show less nonspecific binding to the platelet surface than polyclonal reagents; thus, these reagents may show greater specific binding to their cell-bound ligand (28, 29). We, therefore, compared the binding of polyclonal and monoclonal anti-IgM antibodies with platelets from a second consecutive series of 35 normal volunteers, 48 patients with ITP and 12 thrombocytopenic patients who did not have ITP. We observed that platelets from normal individuals bound approximately the same amount of the monoclonal and polyclonal antibodies (Table III). In addition, platelets from each of 12 thrombocytopenic patients who did not have ITP bound amounts of monoclonal anti-IgM which fell within the normal range. Platelets from 35 of 48 ITP patients bound an increased amount of polyclonal anti-IgM and 30 of 48 bound an increased amount of monoclonal anti-IgM. There was strong concordance between positive tests and negative tests when the platelets of the same individuals were studied using both reagents (P < 0.05). We also observed a positive correlation between the extent of binding of each labeled antibody to ITP platelets (r = 0.79, Fig. 9). However, platelets from 5 ITP patients which bound significantly increased amounts of polyclonal anti-IgM bound amounts of monoclonal anti-IgM which clearly fell within the normal range. In two cases, we noted a borderline elevation in the binding of the monoclonal reagent that was associated with a normal level of binding of polyclonal anti-IgM (Fig. 9).

Presence of IgM anti-platelet antibodies in ITP plasma. These findings suggest that increased amounts of IgM are often present on ITP platelets. The data also suggest that IgM antiplatelet antibody may initiate binding of C3 to the platelet surface. We, therefore, sought to determine directly if warm-reacting IgM anti-platelet antibodies were present in the plasma of some patients with ITP and whether they activated complement.

We studied the plasmas from four patients with ITP who had increased levels of platelet-associated IgM. The plasmas from two of these four patients placed increased amounts of IgM onto normal platelets (1.28 and 1.43% binding of 125I anti-IgM) when compared with normal plasma (0.40±0.38% binding of 125I anti-IgM) (mean±2 SD, n = 53). These two patient plasmas and the IgM fractions isolated from them also caused C3 consumption, as assessed by effective molecule titration (not shown), and the deposition of 3H-C3 onto the platelet surface (Table IV). These IgM fractions did not contain IgG that was detectable by Ouchterlony analysis. The ability of these IgM proteins to place 3H-C3 on normal platelets was not diminished after incubation with an anti-IgG immunoadsorbent capable of binding 2 mg of IgG. The IgG fraction isolated from a patient with anti-PIA1 antibody also caused platelet C3 deposition as previously reported (27).

### Table III. Binding of Polyclonal and Monoclonal 125I Anti-IgM to Platelets

<table>
<thead>
<tr>
<th>Source of platelets</th>
<th>125I-Polyclonal anti-IgM (mean±2 SD)</th>
<th>125I-Monoclonal anti-IgM (mean±2 SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normals (n = 35)</td>
<td>0.06±0.07*</td>
<td>0.05±0.06</td>
</tr>
<tr>
<td>ITP (n = 48)</td>
<td>0.32±0.34</td>
<td>0.21±0.34</td>
</tr>
<tr>
<td>Thrombocytopenic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>controls (n = 12)</td>
<td>0.08±0.09</td>
<td>0.06±0.08</td>
</tr>
</tbody>
</table>

* Platelet-bound radioactivity (mean±2 SD) expressed as a percentage of the total available radioactivity.

### Figure 9. Relationship between the percentage of binding of 125I-polyonal (rabbit) anti-IgM, and 125I-monoclonal (murine) anti-IgM to platelets from patients with ITP.

### Discussion

It is generally accepted that the platelets from most patients with ITP have increased levels of IgG on their surface. The platelets of some ITP patients have increased levels of C3 as well. Several investigators have observed that the platelets from a subset of ITP patients have increased C3 on their surface without a detectable increase in IgG. Since this increased C3 on the platelet surface may have been caused by complement activation initiated by another class of antibody, we examined the level of PA-IgM on ITP platelets.

We first established the integrity of our radiolabeled IgG anti-IgM antibody using human erythrocytes that were quantitatively coated with 3H-IgM anti-A. We found that we could detect the binding of labeled anti-IgM to as few as 50 IgM anti-A molecules on the surface of the erythrocyte, and that

### Table IV. C3 Binding to Platelets Caused by IgM Anti-Platelet Antibody in ITP Plasma

<table>
<thead>
<tr>
<th>Anti-platelet antibody</th>
<th>Platelet C3 deposition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 1</td>
<td>300 3,500</td>
</tr>
<tr>
<td>IgM fraction</td>
<td>150 1,900</td>
</tr>
<tr>
<td>Patient 2</td>
<td>190 6,400</td>
</tr>
<tr>
<td>IgM fraction</td>
<td>80 3,200</td>
</tr>
<tr>
<td>IgG fraction</td>
<td>140 &lt;500</td>
</tr>
<tr>
<td>IgM fraction adsorbed</td>
<td>80 3,000</td>
</tr>
<tr>
<td>Anti-PIA1 antibody, IgG fraction</td>
<td>210 15,900</td>
</tr>
<tr>
<td>Normal donors (n = 5), IgM fraction</td>
<td>105 4,600</td>
</tr>
</tbody>
</table>

Gel filtered platelets were incubated in the presence of a source of antibody and autologous plasma containing 3H-C3 as a source of complement. In the absence of antibody <500 molecules of C3 bound per platelet.
saturable binding of the $^{125}$I anti-IgM to IgM-coated cells could be demonstrated. Moreover, labeled anti-IgM showed minimal binding to IgG-coated erythrocytes. We then studied the binding of $^{125}$I anti-IgM to human platelets. Since the stoichiometry of binding of the labeled anti-IgM to platelet-bound IgM is unknown, we expressed our data in terms of the percentage of labeled anti-IgM that bound to normal or patient platelets. We observed that platelets from normal individuals bound more $^{125}$I-IgG anti-IgM than an equivalent amount of control $^{125}$I-IgG, which was consistent with a low level of IgM on the normal platelet surface. Furthermore, platelets from 50 to 60% of patients with ITP had increased levels of IgM on their surface compared with normal platelets. The increase in platelet IgM was generally associated with increased levels of platelet C3. This relationship between platelet IgM and platelet C3 was noted in patients with ITP irrespective of their platelet count and in patients who were receiving corticosteroids, as well as in those who had previously undergone splenectomy. Therefore, the previously reported association between the level of platelet IgG and platelet C3 (12, 14, 16, 30) could be mediated in some cases by the concurrent presence of IgM anti-platelet antibodies.

There is wide variation in the reported incidence of such IgM antibodies in ITP and other platelet disorders. There is also little agreement as to the level of IgM on platelets (15–22). However, our work is in accord with that of several groups of investigators who observed, using a variety of techniques, that many patients with active ITP have increased amounts of IgM on their platelets (16, 10, 22). The variation in the incidence of increased platelet-bound IgM may reflect either differences in the sensitivity of the assay systems or differences in the patient populations in which the measurements were made.

The enhanced binding of anti-IgM to ITP platelets, which we and others have observed, is most likely due to the presence of IgM anti-platelet antibodies and is not the result of an in vitro artifact for two reasons. First, the increased binding of anti-IgM to ITP platelets was not due to enhanced binding of the radiolabeled ligand itself. ITP platelets did not bind equivalent amounts of radiolabeled antibodies that recognize IgM, IgG, and C3. Second, ITP platelets bound an amount of labeled normal rabbit IgG which was essentially identical to the amount that bound to normal platelets.

It is also unlikely that our finding of increased IgM on ITP platelets is due solely to nonspecific adsorption of serum proteins or particulate matter to ITP platelets in vivo (8, 9, 31, 32). The level of platelet IgM present on ITP platelets appears comparable to the amount of platelet-bound IgG, although the serum concentration of IgM is $\sim 1/10$ that of IgG. Second, using a polyclonal anti-IgM reagent, we did not observe an elevation in platelet-IgM in the two patients we studied who had a high concentration of IgM paraprotein in their sera. In addition, we found a strong correlation between the amount of IgM on ITP platelets and the amount of C3 on ITP platelets; similar correlations were not as pronounced between PA-IgG and either platelet-IgM or platelet-C3. This finding suggests that C3 is present on the platelet because complement was activated by IgM which bound to the platelet either as anti-platelet antibody or as part of an immune complex. Finally, we directly demonstrated the presence of warm reacting, complement-fixing IgM anti-platelet antibodies in the plasma of two patients with ITP.

We also studied the possibility that recently developed monoclonal antibodies to human immunoglobulins might prove to be superior reagents for the detection of increased PA-IgM because of their lower nonspecific binding to cell surfaces (28, 29). However, our use of a monoclonal antiligulin reagent did not enhance the clinical sensitivity of this radioimmunooassay as applied to measurement of PA-IgM. Although a good correlation was found between the polyclonal and monoclonal ligands, in several cases increased IgM was detected only with the polyclonal reagent (Fig. 9). The reason for this result is uncertain. Allotypic restriction has been described among autoantibodies in autoimmune hemolytic anemia and other disorders (33). It is not known whether there are similar antigenic restrictions among autoreactive antiplatelet antibodies and if the epitope recognized by some monoclonal anti-IgM antibodies is uniformly present on all IgM anti-platelet antibodies.

In this entire series, increased PA-IgM was found on the platelets of only 4 of 44 thrombocytopenic patients who did not have ITP; in two patients, drug-dependent thrombocytopenia was suspected which, in fact, may have been mediated by anti-platelet antibody. Therefore, the finding of increased amounts of platelet-bound IgM on ITP platelets in this study appears to be a less sensitive, but a more specific serologic marker for ITP than is the finding of increased platelet-IgG (Fig. 7). This may reflect the lower serum concentrations of IgM as compared with IgG, the lack of a receptor on platelets for the heavy chain of the IgM molecule, or possibly the transient nature of IgM antibody production to most platelet antigens. Studies in other patient populations, such as additional patients with IgM paraproteinemia, may define other circumstances in which increased amounts of PA-IgM are present.

The finding of warm-reacting IgM antibodies in ITP plasma was surprising, and differs from the reported findings in autoimmune hemolytic anemia. The antigen recognized by the IgM antiplatelet antibodies is unknown. The results of recent studies indicate that some IgG autoantibodies in ITP may be directed at determinants on glycoproteins IIb and IIIa (34–36). It will be of interest to determine whether similar antigens are recognized by IgM antibodies. Alternatively, some investigators have suggested that the IgM antibodies may recognize allotypic or idiotypic portions of the platelet-bound IgG molecule itself (20). Additional study will be required to identify the antigen(s) recognized by these antibodies.

Finally, we asked whether the presence of IgM antibody was more likely to occur in certain clinically distinct subgroups of patients with ITP or whether PA-IgM played a role in the clinical course and management of this disease. It is possible, for example, that IgM antibodies directly injure platelets, and lead to their removal by nonimmunologic mechanisms. In agreement with other groups of investigators, we found a complex immunologic profile on ITP platelets (Table II). However, we did not observe a relationship between the level of PA-IgM, as an independent variable, and the platelet count. In part, this may relate to the heterogeneous population studied, which included adults and children, acute and chronic ITP, and both newly diagnosed and heavily treated patients. In part, this may also reflect the fact that the platelet count is a dynamic value that is dependent upon antibody titer and class, efficiency of clearance by the phagocytic system, and extent of marrow production. Binding of C3 to erythrocytes, initiated by IgM antibodies, plays a major role in the site and
rate of removal of these cells from the circulation. However, a larger prospective study of a more homogeneous patient population will be needed to determine whether the presence of IgM and C3 on platelets is an important determinant of platelet count, platelet function, site of sequestration, or response to therapy in ITP.

Acknowledgments

We thank Mrs. Diane Tate and Mrs. Patricia Lafferty for preparing this manuscript for publication.

This work was supported by National Institutes of Health (NIH) grants HL-28207 and HL-27068. Dr. Cines is the recipient of a NIH Research Career Development Award 1KO4-HL-00956.

References


